Infirst Later Than Expected With Lipid-Format Ibuprofen, But On Time In Business Plan
This article was originally published in The Tan Sheet
Executive Summary
The London firm announces Unicough cough/cold product’s launch after reviewing clinical trial results, but holds off on a Flarin ibuprofen launch until completing a trial. “We’re very, very pleased with this, although originally we wanted to be there slightly earlier,” says CEO Manfred Scheske.
You may also be interested in...
J&J’s Mylanta, Mylicon Lines Return Via ‘Fixed-Term’ License With Infirst
Unlike other OTC deals J&J made since McNeil Consumer Healthcare’s quality-control problems led to widespread recalls and a consent decree with FDA, the firm is not divesting the digestive health lines. Infirst will manufacture and market the products in the U.S. for an undisclosed period before the brands return to McNeil.
In Brief
Senate backs pre-tax OTC purchases; infirst Healthcare lands $38M investment; Star Scientific faces fraud allegation; Vitamin Shoppe franchise opens in Panama.
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.